Shivani Vaidya

Shivani Vaidya

Auto-generated profile, based on publicly available information

Shivani Vaidya

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Gandhinagar 382355, Gujarat, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DSDilip Sharma
Dilip Sharma
SVSuril Verma
Suril Verma
SVShivani Vaidya
Shivani Vaidya
KKKiran Kalia
Kiran Kalia
VTVINOD TIWARI
VINOD TIWARI
Glucagon-like peptide (GLP)-1 is an incretin hormone exhibiting several pharmacological actions such as neuroprotection, increased cognitive function, cardio-protection, decreased hypertension, suppression of acid secretion, increase in lyposis, and protection from inflammation. The most potent actions are glucose-dependent insulinotropic and glucagonostatic actions, stimulation of β-cell proliferation, enhanced insulin secretion and reduced weight gain in patients with type-2 diabetes pertaining to blood glucose control. Despite all these actions, its short half-life (around 2∼min) and degradation by a dipeptidyl peptidase-4 enzyme (DPP-4) limits the therapeutic utility of GLP1. In this review, we have discussed DPP IV-resistant analogs of GLP-1 currently present in clinical trials such as Exenatide, Liraglutide, Semaglutide, Efpeglenatide, Exenatide ER, Ittca 650 (Intarcia), Dulaglutide, Albiglutide, and Lixisenatide. Moreover, we have also discussed in detail the pharmacology, signaling mechanisms, and pharmacokinetic properties (Cmax, Tmax, T1/2, Vd, and Bioavailability) of DPP IV-resistant analogs of (GLP-1). Interestingly, GLP-1 agonist drugs have shown better potential to treat type-2 diabetes mellitus (T2DM) as compared to currently used drugs in clinics without causing the side effects of hypoglycemia and weight gain.

23 December 2017 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
VFValencia Fernandes
Valencia Fernandes
DSDilip Sharma
Dilip Sharma
SVShivani Vaidya
Shivani Vaidya
SPShantanu P.A
Shantanu P.A
YGYun Guan
Yun Guan
VTVINOD TIWARI
VINOD TIWARI
Introduction: Current pharmacotherapeutics for neuropathic pain offer only symptomatic relief without treating the underlying pathophysiology. Additionally, they are associated with various dose-limiting side effects. Pain research in the past few decades has revolved around the role of oxidative-nitrosative stress, protein kinases, glial cell activation, and inflammatory signaling cascades but has failed to produce specific and effective therapies. Areas covered: This review focuses on recent advances in cellular and molecular mechanisms of neuropathic pain that may be translated into future therapies. We discuss emerging targets such as WNT signaling mechanisms, the tetrahydrobiopterin pathway, Mrg receptors, endogenous lipid mediators, micro-RNAs and their roles in pain regulation. Recent evidence is also presented regarding genetic and epigenetic mechanisms of pain modulation. Expert opinion: During chronic neuropathic pain, maladaptation occurs in the peripheral and central nervous systems, including a shift in microglial phenotype from a surveillance state to an activated state. Microglial activation leads to an altered expression of cell surface proteins, growth factors, and intracellular signaling molecules that contribute to development of a neuroinflammatory cascade and chronic pain sensitization. Specific targeting of these cellular and molecular mechanisms may provide the key to development of effective neuropathic pain therapies that have minimal side effects.

1 May 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
SVShivani Vaidya
Shivani Vaidya
PSP.A. Shantanu
P.A. Shantanu
VTVINOD TIWARI
VINOD TIWARI

13 September 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
PSP. A. Shantanu
P. A. Shantanu
DSDilip Sharma
Dilip Sharma
MSMonika Sharma
Monika Sharma
SVShivani Vaidya
Shivani Vaidya
KSKuhu Sharma
Kuhu Sharma
VTVINOD TIWARI
VINOD TIWARI

20 February 2025 in Neuropharmacology
Verified
Journal Article
Closed access
SVShivani P. Vaidya
Shivani P. Vaidya
RARoberta G. Anversa
Roberta G. Anversa
PPPaulo Pinares-Garcia
Paulo Pinares-Garcia
LWLeigh C. Walker
Leigh C. Walker
NPNatasha Pracejus
Natasha Pracejus
ALAndrew J. Lawrence
Andrew J. Lawrence

12 February 2021 in Asia Pacific Journal of Public Health
Verified
Journal Article
Closed access
PDF file
SVShivani Vaidya
Shivani Vaidya